PARP Inhibition in the Treatment of Pancreatic Cancer: Current and Future Perspectives on Personalized Therapy

Download All
Learn how experts around the world use PARP inhibitors to optimally manage patients with pancreatic cancer and BRCA1/2 or other alterations causing homologous repair deficiency with focused commentaries, a podcast series, an expert video roundtable, and downloadable slideset.
Dirk Arnold, MD, PhD
Philip Agop Philip, MD, PhD, FRCP

ClinicalThought Commentaries

With the approval of olaparib, how will your treatment of patients with pancreatic cancer change?

Dirk Arnold, MD, PhD Released: October 5, 2021

How might the use of PARP inhibitors evolve in the treatment of pancreatic cancer? Read this commentary from Dr Philip Philip.

Philip Agop Philip, MD, PhD, FRCP Released: January 31, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings